Corona Remedies IPO Opens December 8: Key Details & What Investors Should Know
By Shishta Dutta | Updated at: Dec 4, 2025 02:32 PM IST
4 December 2025 – Corona Remedies, a pharmaceutical company developing and marketing products across women’s health, cardiology, pain management, and urology among others, has announced that its IPO will be open from 8 December to 10 December 2025. Corona Remedies IPO is a book build issue of ₹655.37 crores. The issue is entirely an offer for sale of 0.62 crore shares of ₹655.37 crore. The IPO price band is set at ₹1008.00 to ₹1062.00 per share
Important Upcoming Dates
The IPO will remain open for subscription from December 8 to December 10, 2025. Ahead of the public issue, the company will sell shares to anchor investors on December 5. The basis of allotment, refund initiation and credit of shares to demat accounts is expected to be finalised on 11 December 2025.
The equity shares of Corona Remedies are proposed to be listed on both the BSE and NSE on December 15, 2025, subject to obtaining regulatory approvals
Corona Remedies Price Band, Lot Size and Application Details
Corona Remedies IPO price band is set at ₹1008.00 to ₹1062.00 per share. The lot size for an application is 14. The minimum amount of investment required by a retail is ₹14,868 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,08,152, and for bNII, it is 68 lots (952 shares), amounting to ₹10,11,024.
Corona Remedies Financials
Corona Remedies Ltd. delivered strong financial performance, with revenue rising 18% and profit after tax increasing 65% between FY24 and FY25. For the year ending March 31, 2025, the company reported total income of ₹1,202.35 crore and PAT of ₹149.43 crore, supported by EBITDA of ₹245.91 crore. Total assets grew to ₹929.86 crore, while net worth increased to ₹606.34 crore. Reserves and surplus stood at ₹545.18 crore. By June 30, 2025, assets rose to ₹1,012.38 crore and borrowing increased to ₹106.65 crore.
Company Profile & Market Position of Corona Remedies IPO
Corona Remedies is a pharmaceutical organisation that develops, formulates, and markets a diversified portfolio of medicines in various therapeutic areas, including but not limited to women’s healthcare, cardio-diabeto (cardiac + diabetes), pain management, urology, etc. As of mid-2025, the company has many manufacturing and R&D facilities and has made a mark amongst the fastest-growing players in the Indian pharma industry.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
